VA-CSP-407, NCI-T94-0131O, PIVOT-1,
CLB-9492 High Priority Clinical Trial Phase III Randomized Study
of Prostatectomy vs Expectant Observation With Palliative Therapy for Stage
I/II Prostate Cancer (PIVOT).
Chairperson: Timothy James Wilt. Telephone: 612-725-2000,
ext 2681. Lead organization: Veterans Administration Cooperative Studies
Program Coordinating Center. Age range: 75 and under.
RPCI-DS-95-35, NCI-G97-1352
Phase III Study of Epidural Hydromorphone vs Intravenous Hydromorphone
in Postoperative Radical Prostatectomy Patients.
Chairperson: Robert P. Sands, Jr. Telephone: 716-845-8630.
Lead organization: Roswell Park Cancer Institute. Age range: 18-70.
MRC-PR05, EU-94033 Phase
III Randomized Double-Blind Study of Clodronate vs Placebo in Patients
With Prostate Cancer Metastatic to Bone Who Are Commencing or Responding
to Initial Hormone Therapy.
Chairperson: David P. Dearnaley. Telephone: 0181-642-6011
(England). Lead organization: United Kingdom Medical Research Council.
Age range: any age.
PROG-9509 Phase III
Randomized Study of Conventional vs High-Dose Radiotherapy Using Conformal
Photons With a Proton Boost in Stage I/II Prostate Cancer.
Chairperson: Anthony L. Zietman. Telephone: 617-726-8150.
Lead organization: Proton Radiation Oncology Group. Age range: any age.
MSKCC-97007, NCI-G97-1232
Phase II/III Diagnostic Study of C11-Methionine and 2-F18-Fluoro-2-deoxy-D-Glucose
(FDG) Positron Emission Tomography (PET) Imaging in Patients With Progressive
Prostate Cancer.
Chairperson: Steven M. Larson. Telephone: 212-639-7373.
Lead organization: Memorial Sloan-Kettering Cancer Center. Age range: not
specified.
CWRU-1894, NCI-G97-1360
Phase III Study of Adjuvant Estramustine and Etoposide vs Observation Following
Radical Prostatectomy for Stage II, III, or IV Prostate Cancer.
Chairperson: Cindy Connell. Telephone: 216-844-3180.
Lead organization: Ireland Cancer Center at Case Western Reserve University.
Age range: 18-70.
AG-3340-009 Phase III
Randomized Study of Matrix Metalloproteinase Inhibitor AG3340 in Combination
With Mitoxantrone and Prednisone in Patients With Hormone Refractory Prostate
Cancer.
Chairperson: Mary Collier. Telephone: 619-622-8036.
Lead organization: Agouron Pharmaceuticals, Inc. Age range: 18 and over.
CLB-9583 Phase III Randomized
Study of Antiandrogen Withdrawal Alone vs Antiandrogen Withdrawal Plus
Ketoconazole and Hydrocortisone for Hormone-Refractory Prostate Cancer.
Chairperson: Eric J. Small. Telephone: 415-885-3780.
Lead organization: Cancer and Leukemia Group B. Age range: any age.
CAN-OCOG-V95-0687, NCI-V95-0687,
CAN-NCIC-PR5 Phase III Randomized Study of a Standard vs Shortened
Radiotherapy Fractionation Schedule for Localized Prostate Cancer.
Chairperson: Himu R. Lukka. Telephone: 905-387-9495.
Lead organization: Ontario Clinical Oncology Group. Age range: any age.
MRC-RT01, EU-98005 Phase
III Randomized Comparison Study of Conformal Standard Radiotherapy vs Conformal
High Dose Radiotherapy in Addition to Neoadjuvant Androgen Deprivation
in Patients With Localized Prostate Cancer.
Chairperson: David P. Dearnaley. Telephone: 0181-642-6011
(England). Lead organization: United Kingdom Medical Research Council.
Age range: not specified.
MSKCC-98014, NCI-G98-1445
Phase III Randomized Study of the Effect of a Diet Low in Fat and High
in Soy, Fruits, Vegetables, Green Tea, Vitamin E, and Fiber on PSA Levels
in Patients With Prostate Cancer.
Chairperson: Moshe Shike. Telephone: 212-639-7230.
Lead organization: Memorial Sloan-Kettering Cancer Center. Age range: 18
and over.
MDA-DM-95231, NCI-G96-1044
Phase III Study of Chemo/ Hormonal Therapy vs Androgen Ablation Alone as
Initial Therapy in Unresectable/Metastatic Adenocarcinoma of the Prostate.
Chairperson: Randall E. Millikan. Telephone: 713-792-2830.
Lead organization: University of Texas M.D. Anderson Cancer Center. Age
range: no age specified.
E-8892, CLB-E8892 Phase
III Randomized Study of Orchiectomy or LHRH Analogue Plus Flutamide With
vs Without Suramin and Hydrocortisone in Advanced Adenocarcinoma of the
Prostate.
Chairperson: Robert L. Comis. Telephone: 215-893-6440.
Lead organization: Eastern Cooperative Oncology Group. Age range: 18 and
over.
CLB-9480, INT-0159, SWOG-9452
Phase III Randomized Study of Low- vs Intermediate- vs High-Dose Suramin
for Advanced Hormone-Refractory Prostate Cancer.
Chairperson: Richard L. Schilsky. Telephone: 773-702-6180.
Lead organization: Cancer and Leukemia Group B. Age range: 18 and over.
CAN-NCIC-PR3, NCI-T94-0110O,
E-JPR03 Phase III Randomized Study of Total Androgen Blockade With
vs Without Pelvic Irradiation for Stage T3-4, N0, M0 Adenocarcinoma of
the Prostate.
Chairperson: Padraig R. Warde. Telephone: 416-946-2122.
Lead organization: NCIC-Clinical Trials Group. Age range: under 80.
EORTC-30846 Phase III
Immediate vs Delayed Endocrine Therapy With Zoladex and Cyproterone Acetate
for Patients With pN1-3M0 Carcinoma of the Prostate.
Chairperson: Fritz H. Schroeder. Telephone: 31-10-4633607
(Netherlands). Lead organization: EORTC Genito-Urinary Tract Cancer Cooperative
Group. Age range: any age.
EORTC-30921 Phase III
Randomized Trial of Strontium-89 vs Palliative Local Radiotherapy in Patients
With Hormone-Refractory Prostate Cancer With Painful Osseous Metastases.
Chairperson: G.O.N. Oosterhof. Telephone: 31-24-3616712
(Netherlands). Lead organization: EORTC Genito-Urinary Tract Cancer Cooperative
Group. Age range: any age.
EORTC-30972 Phase III
Randomized Study of Prednisone Alone or in Combination With BMS-182751
in Patients With Advanced Hormone Refractory Adenocarcinoma of the Prostate.
Chairperson: Cora N. Sternberg. Telephone: 011-39-6-5240-6812
(Italy). Lead organization: EORTC Genito-Urinary Tract Cancer Cooperative
Group. Age range: over 18.
EORTC-30891 Phase III
Comparison of Early vs Delayed Endocrine Manipulation (Orchiectomy or LHRH
Agonist Therapy) in Previously Untreated Patients With Nonmetastatic Asymptomatic
Carcinoma of the Prostate.
Chairperson: Urs E. Studer. Telephone: 031-632-3621
(Switzerland). Lead organization: EORTC Genito-Urinary Tract Cancer Cooperative
Group. Age range: 80 and under.
CAN-NCIC-PR6 Phase III
Randomized Study of Mitoxantrone and Prednisone With or Without Clodronate
in Patients With Hormone Refractory Metastatic Prostate Cancer and Pain.
Chairperson: D. Scott Ernst. Telephone: 403-670-1761.
Lead organization: NCIC-Clinical Trials Group. Age range: any age.
EORTC-22961 Phase III
Study of Long Term Adjuvant Hormonal Treatment With LHRH Analogue (Goserelin)
vs No Further Treatment in Locally Advanced Prostatic Carcinoma Treated
by External Irradiation and a Six Month Combined Androgen Blockade.
Chairperson: Michel Bolla. Telephone: 33 476765506
(France). Lead organization: EORTC Radiotherapy Cooperative Group. Age
range: any age.
EORTC-22911 Phase III
Randomized Study of Postoperative External Radiotherapy vs No Immediate
Further Treatment in Patients With pT3 pN0 Prostatic Adenocarcinoma.
Chairperson: Michel Bolla. Telephone: 33 476765506
(France). Lead organization: EORTC Radiotherapy Cooperative Group. Age
range: 75 and under.
SWOG-9346, CLB-9594, INT-0162,
E-S9346 Phase III Randomized Study of Intermittent vs Constant Combined
Androgen Deprivation (Flutamide/Leuprolide or Flutamide/Goserelin) in Stage
D2 Prostate Cancer Responsive to Such Therapy.
Chairperson: Maha Hadi A. Hussain. Telephone: 313-745-4700.
Lead organization: Southwest Oncology Group. Age range: adult.
RTOG-9601, RTOG-R9601, SWOG-R9601
Phase III Randomized, Double-Blind Study of Radiotherapy With vs Without
Bicalutamide in Patients With PSA Elevation Following Radical Prostatectomy
for pT3 N0 Carcinoma of the Prostate.
Chairperson: William U. Shipley, Telephone: 617-726-8146.
Lead organization: Radiation Therapy Oncology Group. Age range: any age.
RTOG-9608 Phase III
Study of Total Androgen Suppression vs Total Androgen Suppression Plus
Definitive External Beam Irradiation for Pathologic Lymph Node Positive
Adenocarcinoma of the Prostate.
Chairperson: Colleen A. Lawton. Telephone: 414-257-5726.
Lead organization: Radiation Therapy Oncology Group. Age range: not specified.
RTOG-9714, NCI-P97-0124, NCCTG-R9714
Phase III Randomized Study of Palliative Radiation Therapy for Bone Metastases
From Breast or Prostate Cancer.
Chairperson: William F. Hartsell. Telephone: 708-723-8030.
Lead organization: Radiation Therapy Oncology Group. Age range: 18 and
over.
RTOG-9413 Phase III
Randomized Study of Whole-Pelvic Irradiation Followed by a Cone-Down Boost
to the Prostate vs Prostate Irradiation Only and of Neoadjuvant vs Adjuvant
FLUT/ZDX for Adenocarcinoma of the Prostate.
Chairperson: Mack Roach, III. Telephone: 415-476-4815.
Lead organization: Radiation Therapy Oncology Group. Age range: any age.
RTOG-9408 Phase III
Randomized Study of Radiotherapy With vs Without Neoadjuvant Flutamide/
Goserelin in Good-Prognosis, Locally Confined Adenocarcinoma of the Prostate.
Chairperson: David G. McGowan. Telephone: 403-432-8771.
Lead organization: Radiation Therapy Oncology Group. Age range: any age.
Legend for Abbreviations:
AG = Agouron Pharmaceuticals, Inc
CAN-NCIC = National Cancer Institute of Canada
CAN-OCOG = Ontario Clinical Oncology Group
CLB = Cancer & Leukemia Group B
CWRU = Case Western Reserve University
E, EST = Eastern Cooperative Oncology Group
EORTC = European Organization for Research on Treatment
of Cancer
MDA = M.D. Anderson Cancer Center
MRC = United Kingdom Medical Research Council
MSKCC = Memorial Sloan-Kettering Cancer Center
PROG = Proton Radiation Oncology Group
RPCI = Roswell Park Cancer Institute
RTOG = Radiation Therapy Oncology Group
SWOG = Southwest Oncology Group
VA = Veterans Administration Cooperative Studies Program